Triple Burner Peptide Pen
Triple Burner Peptide Pen
Triple Burner Peptide Pen 30mg
Understanding Reta:
This product is a reusable pen system, which uses refill cartridges for precise and convenient delivery.
Product Strength: 30mg per 3ml cartridge
Storage: Keep refrigerated between 2–8 °C (36–46 °F) to maintain potency and stability.
What It Is
Retatrutide is a novel, investigational injectable medication developed by Eli Lilly. It is the first agent in its class to function as a triple hormone receptor agonist, simultaneously targeting three key metabolic pathways: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCG) receptors . This triple-action mechanism is designed to enhance weight loss and glycemic control beyond the capabilities of existing dual or single agonists.
How It Works
Unlike single-agonist drugs like semaglutide (Wegovy/Ozempic) or dual-agonist drugs like tirzepatide (Mounjaro/Zepbound), retatrutide’s triple mechanism offers a multi-pronged approach to metabolism :
GLP-1 Receptor Agonism: Reduces appetite, increases satiety, and slows gastric emptying, leading to lower calorie intake.
GIP Receptor Agonism: Enhances insulin secretion, improves fat metabolism, and amplifies the appetite-suppressing effects of GLP-1.
Glucagon Receptor Agonism: This is the differentiating factor. Glucagon works to increase energy expenditure and promote the burning of stored fat (lipolysis), helping the body achieve a calorie deficit more efficiently .
Key Benefits & Clinical Efficacy
Retatrutide is currently in Phase III clinical trials, but data released to date shows unprecedented efficacy:
Superior Weight Reduction: Phase II trials showed patients lost an average of 24.2% of their body weight in 48 weeks at the highest dose, outperforming results seen with semaglutide (~15%) and tirzepatide (~21%) over similar or longer periods . Phase III data confirms this, with participants taking a 12 mg weekly dose losing an average of 28.7% (approximately 71 lbs) of their body weight after 68 weeks . In this trial, 58.6% of participants achieved at least 25% weight loss, and 23.7% achieved at least 35% weight loss .
Exceptional Glycemic Control: For patients with type 2 diabetes, retatrutide has demonstrated significant reductions in HbA1c. In the Phase III TRANSCEND-T2D-1 trial, participants achieved up to a 2.0% reduction in HbA1c from a baseline of 7.9% after 40 weeks, alongside a 16.8% reduction in body weight .
Improved Metabolic and Cardiovascular Health: Beyond weight and blood sugar, retatrutide has been shown to reduce markers of cardiovascular risk. In trials, the 12 mg dose lowered systolic blood pressure by an average of 14.0 mmHg and improved non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein .
Additional Benefits: The drug has also shown promise in reducing pain associated with knee osteoarthritis, with patients reporting significant improvements on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) .
Status: Retatrutide is currently in Phase III clinical trials, with results expected throughout 2026. It is not yet approved for sale by the FDA, MHRA, or other global regulatory bodies .
Possible Side Effects & Warnings
Common Side Effects: The most common side effects are gastrointestinal in nature and dose-dependent, including nausea, diarrhea, constipation, vomiting, and decreased appetite . These are typically most pronounced during the dose-escalation phase.
Less Common Side Effects: A unique side effect reported in trials is dysesthesia (a sensation of burning, prickling, or tingling of the skin), which occurred in a small percentage of patients .
Excessive Weight Loss: In clinical trials, a notable number of participants discontinued the medication due to excessive weight loss, highlighting the drug's potency. Careful monitoring is required to prevent malnutrition and significant loss of lean muscle mass .
Important Safety Considerations & Warnings
Investigational Status: Retatrutide is not FDA-approved. It is available only through participation in registered clinical trials.
Black Box Warning (Class Effect): As with other incretin-based medications, there is a potential risk of thyroid C-cell tumors. It is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Contraindications: Should not be used by individuals with a history of pancreatitis, severe gastrointestinal disease, or those who are pregnant or breastfeeding.
Long-Term Use: The long-term safety profile, particularly regarding muscle mass retention and nutritional status, is still being evaluated in ongoing trials .
Disclaimer: This information is for general knowledge and educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not approved for general medical use. It should only be used under the guidance of a licensed healthcare professional within the context of an approved clinical trial.